Articles Accepted

ENHANCING GASTRIC ULCER MANAGEMENT: NOVEL INSIGHTS FROM TERAZOSIN-PANTOPRAZOLE COMBINATION THERAPY
by Dr. Doshi Gaurav Mahesh, 09 Oct 2023
Co-Author(s): Teresa J Vadakutt

In this present study, we explored a novel approach to gastric ulcer management by investigating the therapeutic potential of Terazosin, an alpha-1 adrenergic receptor inhibitor, in combination with Pantoprazole, a common anti-ulcer agent. Employing an ethanol-induced rat-gastric ulcer model, the study demonstrated that Terazosin pre-treatment significantly reduced ulcer formation, with the Terazosin-Pantoprazole combination exhibiting superior mucosal protection compared to Pantoprazole alone. Histopathological analysis revealed preserved mucosal structure and reduced neutrophil infiltration, indicating an anti-inflammatory effect. At a molecular level, the combination treatment groups exhibited elevated levels of phosphoglycerate kinase 1 (PGK-1), a vital enzyme in cellular energy metabolism, while inflammatory markers IkappaB kinase (IKK) and interleukin- 6 (IL-6) were significantly reduced, signifying mitigation of inflammation. These findings of the three different combinations of Terazosin with Pantoprazole indicate that this can be a potential approach for the treatment of gastric ulcers and can help in reducing the existing Pantoprazole dose.

Current Issue
December 2023
Quick Contact